Reimagining Medicine
Company overview
Financial review
2023 priorities
Appendix
GROWTH
Cosentyx® Q4 sales impacted mainly by a revenue deduction true-up
related to prior quarters in the US and China COVID lockdowns
Sales evolution
USD m, % cc
Ex-US
US
-9% / -2%1
+5%
1,243
4,718
4,788
1,080
473
1,835
2,018
447
*Cosentyx®
Q4 performance
US: -18%-6%. Impacted by a RD true-up relating to prior quarters in
2022 driven primarily by a higher Medicaid channel mix
Ex-US: +5% (cc), growth driven by core indications
China: Impacted by COVID and stock compensation provision for 2023
NRDL re-listing
Volume continues to grow across key geographies
FY sales USD 4.8bn (+5% cc) driven by ex-US (+20% cc)
Future growth mainly driven by LCM
770
2,883
2,770
633
2021
2022
Q4
2021
2022
2023: Expect sales broadly in line with PY (H2 growth and H1 decline²)
2024+: LCM anticipated to drive next phase of growth
FY
LCM-life cycle management.
RD - revenue deduction. NRDL - national reimbursement drug list.
1. US CosentyxⓇ sales growth was impacted by a revenue deduction true-up, which was related to prior quarters in 2022. Global sales
declined -9% in Q4 vs. PY (decline would have been -2% without the true-up). US sales declined -18% in Q4 vs. PY (decline would have been -6% without the true-up). 2. Expect continued RD dynamics in US.
24 Investor Relations | Q4 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation